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Position Statement
and understanding of the cough aetiology. CICAD
Children and Adults: Diagnosis and Assessment)
guideline for the assessment and management of persi
children and adults. CICADA was developed by a mu
expert committee after a needs assessment by clinic
rised at http://www.lungfoundation.com.au/content/v
The guideline development process is further describeMJA • Volume 192 NumABSTRACT
• Cough is a common and distressing symptom that results in 
significant health care costs from medical consultations and 
medication use.
• Cough is a reflex activity with elements of voluntary control 
that forms part of the somatosensory system involving visceral 
sensation, a reflex motor response and associated 
behavioural responses.
• At the initial assessment for chronic cough, the clinician 
should elicit any alarm symptoms that might indicate a serious 
underlying disease and identify whether there is a specific 
disease present that is associated with chronic cough.
• If the examination, chest x-ray and spirometry are normal, 
the most common diagnoses in ADULTS are asthma, rhinitis 
or gastro-oesophageal reflux disease (GORD). The most 
common diagnoses in CHILDREN are asthma and protracted 
bronchitis.
• Management of chronic cough involves addressing the 
common issues of environmental exposures and patient or 
parental concerns, then instituting specific therapy.
• In ADULTS, conditions that are associated with removable 
causes or respond well to specific treatment include 
protracted bacterial bronchitis, angiotensin-converting 
enzyme inhibitor use, asthma, GORD, obstructive sleep 
apnoea and eosinophilic bronchitis.
• In CHILDREN, diagnoses that are associated with removable 
causes or respond well to treatment are exposure to 
environmental tobacco smoke, protracted bronchitis, asthma, 
motor tic, habit and psychogenic cough.
• In ADULTS, refractory cough that persists after therapy is 
managed by empirical inhaled corticosteroid therapy and 
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speech pathology techniques.ou
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meC gh is a common and distressing symptom that results innificant health care costs from medical consultations anddication use. Non-specific cough suppressant therapy
offers little benefit in managing persistent cough. Successful man-
agement requires a treatment program based on accurate diagnosis
A (Cough in





d in Box 1.
Definitions
Cough is a reflex activity with elements of voluntary control. It forms
part of the somatosensory system that involves visceral sensation, a
reflex motor response and associated behavioural responses.4 Clini-
cally useful definitions of cough are based on the duration of the
symptom, whether it is associated with specific conditions recog-
nised to cause cough, and its response (or lack of response) to
treatment (Box 2). CICADA addresses protracted and chronic
cough, and does not make recommendations for acute cough.
Neurophysiology
The cough reflex is dependent on sensory nerve fibres carried by
the vagi that are responsive to chemical and mechanical stimuli.
These fibres are integrated into a brainstem circuit that is
responsible for generating the basic cough motor pattern that
provides co-ordinated output via phrenic, intercostal, laryngeal
and abdominal motor neurone pathways to the muscles involved
in coughing.5
Cough is a protective reflex, and this function is relevant to
cough that is secondary to the presence of a foreign body or mucus
hypersecretion. Sensitisation of the cough reflex is a feature of
patients with chronic cough and may occur via peripheral and/or
central mechanisms.5 Both chemosensitive and mechanosensitive
cough fibres can be sensitised by inflammation in the airway,
making them more responsive to a given stimulus (peripheral
sensitisation).5 The activity of the brainstem circuitry can be
tonically enhanced by persistent peripheral sensory nerve input,
such that it becomes hyper-responsive to additional input from
cough fibres (central sensitisation). Higher brain centres also
modulate the basic cough reflex.5 Coughing can be voluntarily
initiated and inhibited,6 is highly susceptible to placebo suppres-
sion,4,6 and is diminished during general anaesthesia or sleep.7 The
urge-to-cough sensation, which may or may not precede a cough,
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In Australia, cough is one of the most common reasons for
presenting for a medical consultation.9,10 Epidemiological studies
identify a 5%–10% prevalence of chronic cough in both adults and
children.9 Chronic cough has a negative impact on quality of life in
adults11,12 and in parents of children with chronic cough.9 In
adults, it may be associated with significant psychosocial distur-
bance, including anxiety and depression.13
Diagnosis and assessment
The initial assessment for protracted or chronic cough is intended
to characterise the condition based on history, to elicit any alarm
symptoms or findings that may indicate a serious underlying
disease (Box 3), and to identify whether there is a specific disease
present that is associated with chronic cough (in which case it is
termed “specific cough”).
Specific cough
Specific cough refers to a cough that occurs with a condition
known to be associated with or cause chronic cough. Identification
of the many different conditions that are associated with chronic
cough forms the basis of specific treatment and further investiga-
tion. These conditions can be identified by a probability-based
diagnostic approach (Box 4), by consideration of important condi-
tions not to be missed (Box 5), and by reviewing cough pointers
(eg, quality of cough, such as “brassy” cough, suggesting tracheo-
malacia; coexisting wheeze, suggesting asthma).14 Methods for
systematic and objective cough assessment are also available, but
at present they are mainly used in research settings or specialised
cough clinics.15
The GRADE system
The Grading of Recommendations Assessment, Development and
Evaluation (GRADE) system for classifying recommendations
made in guidelines2 was developed by a multinational group of
experts in research methods and evidence-based medicine. Based
on an assessment of the strength of evidence, and possible adverse
effects and costs of using the therapy, the CICADA panel used the
GRADE system to determine the strength of cough treatment
recommendations as strong, weak, or “no specific recommenda-
tion” (Box 1).
1 Process used in developing this document
From May 2006 to April 2009, members of CICADA (Cough in 
Children and Adults: Diagnosis and Assessment) recurrently 
convened (by email, face-to-face and by teleconference) to discuss 
definitions followed by recommendations. The complete document 
will be available in 2010 on the Australian Lung Foundation website 
(http://www.lungfoundation.com.au). CICADA’s recommendations 
are based on a successful problem-based clinical assessment 
method that is widely used in primary care.1 It uses the principles of 
evidence-based medicine and the Grading of Recommendations 
Assessment, Development and Evaluation (GRADE) approach2 to 
determine the strength of treatment recommendations made in 
guidelines: strong, weak, or “no specific recommendation”.
Quoting from Guyatt et al in their article on the GRADE 
classification,2 the implications of a strong recommendation are:
• For patients — most people in your situation would want the 
recommended course of action and only a small proportion would 
not; request discussion if the intervention is not offered;
• For clinicians — most patients should receive the recommended 
course of action;
• For policy makers — the recommendation can be adopted as a 
policy in most situations.
The implications of a weak recommendation are:
• For patients — most people in your situation would want the 
recommended course of action, but many would not;
• For clinicians — you should recognise that different choices will 
be appropriate for different patients and that you must help each 
patient to arrive at a management decision consistent with her or 
his values and preferences;
• For policy makers — policy making will require substantial debate 
and involvement of many stakeholders.
The implications of “no specific recommendation” are that the 
advantages and disadvantages are equivalent, the target population 
has not been identified, and/or there is insufficient evidence on 
which to formulate a recommendation.3
The CICADA multidisciplinary expert committee prepared the 
CICADA guideline. A subgroup (P G G and A B C) with expertise 
in evidence-based techniques and systematic reviews prepared a 
GRADE summary table for each recommendation using the nominal 
group technique. A PubMed search for the highest level of evidence 
relating to each recommendation was performed. The relevant 
citations and their abstracts were sent to CICADA members, who 
used the information to assess each recommendation.
The summary table assigned a grading to each of the domains of 
quality of evidence, balance between desirable and undesirable 
effects, values and preferences, and costs, which were assessed using 
the GRADE descriptors.2 The guideline and summary table were then 
reviewed by the CICADA multidisciplinary expert committee. 
Consensus was achieved using a GRADE grid to record the views of 
committee members, and the strength of recommendations was 
assigned by formal voting rules.3 The final GRADE recommendations 
were based on these votes and considered cough in the context of 
the respective conditions (Box 6). ◆
2 Definitions of cough for clinical practice*
Cough type Definition
Cough A forced expulsive manoeuvre, usually 
against a closed glottis, that is associated 
with a characteristic sound
Acute cough Cough lasting up to 2 weeks
Protracted acute 
cough (in CHILDREN)
Cough lasting 2–4 weeks
Chronic cough (in 
CHILDREN)
Cough lasting more than 4 weeks
Chronic persistent 
cough (in ADULTS)
Cough lasting more than 8 weeks
Specific cough Cough associated with a condition 
recognised to cause cough
Non-specific cough Cough without any specific disease 
association
Refractory cough Cough that persists after therapy
* These definitions were adopted by the Cough in Children and Adults: 
Diagnosis and Assessment panel after consideration. The suggested times are 
indicative only. ◆266 MJA • Volume 192 Number 5 • 1 March 2010
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Management of protracted or chronic cough involves addressing
the common issues of environmental exposures and patient or
parental concerns, then instituting specific therapy. Management
practices for infants and school-age children are differentiated
from those for adults when considered appropriate. Although there
are similarities between the two, there are also substantial differ-
ences.16
Environmental exposures. Tobacco smoke exposure, both active
and environmental, is a significant trigger for cough. Cessation of
parental smoking can successfully reduce cough in children
(GRADE: strong).17 Other potentially relevant exposures include
certain forms of home heating, respiratory irritants (such as
particulates) and proximity to a high level of road traffic. In
ADULTS, the use of angiotensin-converting enzyme (ACE) inhibi-
tors may be associated with persistent cough.18 Management
consists of evaluation of the risks and benefits of ACE inhibitor
therapy and cessation or initiation of alternative therapy, as
appropriate.
Patient and parental concerns. Patients and their carers have
significant concerns and fears in relation to the aetiology and
outcome of a cough and the possible presence of a serious
underlying disease.9 Providing information on the possible cough
aetiology, time course for resolution of cough, and expected
management may help reduce anxiety.19 Education is most effec-
tive when combined with a medical consultation.20 The provision
of written information without health professional consultation
has only modest benefits.21
Specific cough: lower airway disorders
Protracted bacterial bronchitis
A diagnosis of protracted bacterial bronchitis is considered in
patients with a protracted acute cough or a chronic cough that is
wet, moist, or productive and occurs in the absence of other
specific cough diagnoses or cough pointers.14 Chest x-ray and
spirometry are usually normal. Medium-term antibiotic treatment
(2–6 weeks) should lead to complete cough resolution (GRADE:
strong).22 The diagnosis can only be definitive when patients
become asymptomatic with treatment.23
3 Alarm symptoms and findings in chronic cough
In ADULTS
• Haemoptysis
• Smoker with > 20 pack-year smoking history
• Smoker over 45 years of age with a new cough, altered cough, or 
cough with voice disturbance
• Prominent dyspnoea, especially at rest or at night
• Substantial sputum production
• Hoarseness
• Systemic symptoms: fever, weight loss
• Complicated gastro-oesophageal reflux disease (GORD) 
associated with weight loss, anaemia, overt gastrointestinal 
bleeding (haematemesis or melaena), dysphagia, odynophagia, or 
empirical treatment failure for GORD
• Feeding difficulties (including choking or vomiting)
• Recurrent pneumonia
• Abnormal clinical respiratory examination
• Abnormal chest x-ray
In CHILDREN
• Prominent dyspnoea, especially at rest or at night
• Recurrent episodes of chronic, wet or productive cough
• Systemic symptoms: fever, weight loss, failure to thrive
• Feeding difficulties (including choking or vomiting)
• Recurrent pneumonia
• Stridor and other respiratory noises
• Abnormal clinical respiratory examination
• Abnormal chest x-ray ◆
5 Remediable conditions and significant conditions not 
to be missed in people with chronic cough
Conditions with specific remediable causes or usually good treat-
ment response
• Protracted bacterial bronchitis
• Asthma
• Gastro-oesophageal reflux disease
• Obstructive sleep apnoea
In ADULTS
• Angiotensin-converting enzyme inhibitor use
• Eosinophilic bronchitis
In CHILDREN
Motor tic, habitual cough and psychogenic cough
Significant conditions not to be missed
In ADULTS
• Neoplasia of larynx, bronchus, or lung
• Parenchymal lung disease: chronic obstructive pulmonary disease, 
interstitial pulmonary fibrosis, bronchiectasis, sarcoidosis, chronic 
pulmonary collapse
• Infection: tuberculosis, lung abscess, pertussis
• Cardiovascular disease: left ventricular failure, pulmonary 
infarction, aortic aneurysm
In CHILDREN
• Congenital airway abnormalities
• Foreign body inhalation
• Parenchymal lung disease: cystic fibrosis, interstitial pulmonary 
fibrosis, bronchiectasis, sarcoidosis, chronic pulmonary collapse
• Infection: tuberculosis, lung abscess, pertussis ◆
4 Probability-based diagnosis of chronic cough
If examination, chest x-ray and spirometry are normal, the most 








Asthma (if other symptoms are present)
Exposures
Respiratory infection (post-infectious cough)
Tobacco smoke and other pollutants (active, environmental exposure) ◆MJA • Volume 192 Number 5 • 1 March 2010 267
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In CHILDREN Recommended treatment/approach Strength of recommendation†
All cough types Cessation of parental smoking Strong
Cough with allergic 
rhinitis
According to current rhinitis management guidelines, involving topical nasal 





Tonsillectomy and adenoidectomy Weak
Cough with asthma According to current asthma management guidelines, involving education, self-





Medium-term antibiotic therapy (2–6 weeks) for protracted bacterial bronchitis Strong
Cough with GORD Empirical trial of high-dose PPI therapy (eg, any standard-dose PPI twice daily for 8–12 
weeks) if there is a reasonable suspicion that GORD may be contributing to chronic cough
NSR




Address patient/parental stress and concerns Strong
Address exacerbating factors Weak
Minimise use of medications other than demulcents such as honey (if no 
contraindications to its use exist)
Strong
Adopt counsel, watch, wait and review approach Strong
Empirical trial of inhaled corticosteroid therapy NSR
Empirical trial of PPIs NSR
Speech pathology techniques designed to relieve glottal constriction during inspiration 
and to recognise and alter the response to precipitants
NSR
Antitussive therapy with narcotics Strong recommendation 
against use
In ADULTS
Cough with allergic 
rhinitis 
According to current rhinitis management guidelines, involving topical nasal 
corticosteroids, antihistamines and allergen management
Weak
Cough with chronic 
rhinosinusitis
According to current rhinosinusitis management guidelines, involving topical nasal 
corticosteroids, antibiotics and non-specific therapy
Strong
Cough with vocal cord 
dysfunction
Medical management of comorbid conditions (eg, asthma, rhinosinusitis, GORD, 
use of ACE inhibitors)
Weak
Speech pathology techniques designed to relieve glottal constriction during inspiration 





Nasal continuous positive airway pressure Strong
Cough with asthma According to current asthma management guidelines, involving education, self- 








Medium-term antibiotic therapy (2–6 weeks) for protracted bacterial bronchitis Strong
Cough with GORD Empirical trial of high-dose PPI therapy (eg, any standard-dose PPI twice daily for 8–12 
weeks) if there is a reasonable suspicion that GORD may be contributing to chronic cough
Strong
Laparoscopic fundoplication for chronic cough NSR
Non-specific and 
refractory cough
Address patient stress and concerns Strong
Address exacerbating factors Weak
Empirical trial of inhaled corticosteroid therapy Strong
Empirical trial of PPIs Strong
Speech pathology techniques designed to relieve glottal constriction during inspiration 
and to recognise and alter the response to precipitants
Strong
Antitussive therapy with narcotics NSR
ACE = angiotensin-converting enzyme. GORD = gastro-oesophageal reflux disease. NSR = no specific recommendation. PPI = proton-pump inhibitor. * The treatment 
recommendation refers to the efficacy of treatment for cough occurring in association with the conditions specified. † The strength of each recommendation was 
classified by the Cough in Children and Adults: Diagnosis and Assessment panel according to the GRADE system2 (see Box 1 for a description of the process used). ◆
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Asthma is considered as a cause of chronic cough if the cough is
episodic and associated with other features such as expiratory
wheeze and/or exertional dyspnoea, or exhibits an obstructive
ventilatory pattern on lung function testing (particularly if respon-
sive to a bronchodilator). Other suggestive but less definitive
features include the presence of exercise-induced cough or atopy.
The diagnosis should be confirmed by spirometry with a positive
bronchodilator response, or a positive bronchial provocation
challenge. Treatment is according to current asthma management
guidelines24 and involves education, self-management and the use
of inhaled bronchodilators and inhaled corticosteroids. Treatment
is expected to be effective within 2–4 weeks (GRADE: strong).
In CHILDREN, chronic cough without the above features is
seldom due to asthma, and inhaled corticosteroids are not indi-
cated unless there are positive features to suggest asthma.
Eosinophilic bronchitis in adults
In ADULTS, eosinophilic bronchitis includes non-asthmatic eosi-
nophilic bronchitis, eosinophilic asthma, cough-variant asthma
and atopic cough.25 These conditions are characterised by chronic
eosinophilic inflammation of the lower airway (eosinophilic bron-
chitis) that can be recognised from an induced sputum sample
(eosinophils > 3% of non-squamous cells) or bronchoalveolar
lavage (eosinophils > 2%), and are suggested by an elevated
fractional exhaled nitric oxide (FeNO) level (> 47 ppb).26 Manage-
ment in adults involves inhaled corticosteroid therapy, with a
favourable response generally seen within 2–4 weeks (GRADE:
strong).25 As access to eosinophil markers is limited, an empirical
trial of inhaled corticosteroids can be considered where appropri-
ate.
Specific cough: upper airway disorders
Allergic rhinitis
Allergic rhinitis can be diagnosed by eliciting signs and symptoms
of nasal inflammation: nasal itching, nasal blockage, nasal dis-
charge, conjunctivitis and nocturnal snoring. Relevant allergenic
triggers can be identified by measuring allergen-specific IgE levels
using skin prick testing or radioallergosorbent testing, with aller-
gens limited by restriction to likely exposures or by exclusion of
specific allergens. Indiscriminate use of a large number of allergens
is not advised. The management of allergic rhinitis follows current
evidence-based guidelines27 and involves treatment with a topical
nasal steroid, with or without antihistamine (GRADE: weak).
Allergen removal, allergen minimisation or immunotherapy can
also be performed (GRADE: weak). Antihistamines have not been
shown to be efficacious in children.28
The evidence that postnasal drip (discharge) is a significant
cause of cough is tenuous.29 When postnasal drip or discharge is
associated with cough, it is most likely a reflection of coexisting
upper airway disease.30
Chronic rhinosinusitis in adults
In ADULTS, chronic rhinosinusitis as a cause of chronic cough is
suggested by nasal or upper airway symptoms of more than 12
weeks’ duration and at least two of the following symptoms or
signs: anterior and/or posterior mucopurulent drainage, nasal
obstruction, facial pressure, pain or fullness. Other suggestive
symptoms include halitosis, hyposmia or anosmia, headaches,
fatigue, dental pain, a sensation of ear pressure, the presence of
inflammation on examination of a congested nose (discoloured
mucus, oedema of the middle meatus) and/or a computed tomog-
raphy (CT) scan showing evidence of rhinosinusitis.27
Investigation can involve a CT scan of the sinuses. This is
indicated when the diagnosis is uncertain, the patient is not
responding to medical treatment as expected, or surgery is
planned or being considered. Bacterial culture of nasal swabs is
indicated for patients who are not responding to medical therapy
and to guide antibiotic selection. Allergy assessment can be helpful
if there is associated allergic rhinitis. Management is according to
current evidence-based guidelines27 and involves nasal saline
irrigation, intranasal corticosteroid therapy for a minimum trial of
1 month, and oral antibiotic therapy for 3 weeks to 3 months for
purulent chronic rhinosinusitis. Short-course prednisone treat-
ment can be added for associated nasal polyposis (GRADE:
strong).
Obstructive sleep apnoea
Obstructive sleep apnoea (OSA) has been increasingly recognised
to be associated with chronic cough in adults and to a limited
extent in children.31,32 OSA is suggested by a history of snoring
associated with witnessed apnoeas, sleep disturbance or sweating
at night; excessive daytime sleepiness; failure to thrive (in infants);
obesity; enlarged tonsils; or nasal blockage. The diagnosis is
confirmed by polysomnography. Treatment of OSA in ADULTS
involves nasal continuous positive airway pressure (CPAP)
(GRADE: strong).33 Treatment of OSA in CHILDREN involves
nasal CPAP or tonsillectomy and adenoidectomy (GRADE: weak).
Vocal cord dysfunction in adults
In ADULTS, vocal cord dysfunction (VCD) is characterised by
episodic and involuntary narrowing of the vocal cords during
inspiration, leading to symptoms of inspiratory dyspnoea, stridor,
cough, throat tightness and dysphonia.34 The underlying patho-
physiology is thought to be extrathoracic airway hyper-responsive-
ness. Up to 50% of adults with VCD report significant persistent
cough. VCD is diagnosed by observation of vocal fold narrowing
(adduction) on laryngoscopy during a symptomatic episode, or a
fall in inspiratory flow of more than 25% during airway provoca-
tion saline challenge.34 In adults with VCD, the treatment consists
of medical management of comorbid conditions (eg, asthma,
rhinosinusitis, gastro-oesophageal reflux disease [GORD] or ACE
inhibitor use) (GRADE: weak), as well as speech pathology
techniques designed to relieve glottal constriction during inspira-
tion and to recognise and alter the response to precipitants
(GRADE: strong).34,35
Gastro-oesophageal reflux disease
Chronic cough may represent an extraoesophageal manifestation
of GORD, although there is controversy as to cause and effect.36
Cough associated with GORD may result from activation of the
cough reflex by refluxate in the oesophagus, acid-induced laryngi-
tis, laryngopharyngeal reflux, or pulmonary aspiration of reflux-
ate.37 The patient should be assessed for heartburn and
regurgitation and to determine whether GORD alarm symptoms
are present (Box 3). If such symptoms are present, specialist review
and endoscopy may be required. In the absence of alarm symp-
toms, investigation is of limited value.
In ADULTS, an empirical trial of high-dose proton-pump inhib-
itor (PPI) therapy (eg, any standard-dose PPI twice daily for 8–12
weeks) is indicated if there is a reasonable suspicion that GORDMJA • Volume 192 Number 5 • 1 March 2010 269
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should be ceased (GRADE: strong).38 Non-acid reflux is a recently
recognised condition that is associated with extra-oesophageal
symptoms, including cough. The investigation and successful
management of non-acid reflux requires further study. Laparo-
scopic fundoplication is reserved for the small minority of adults in
whom the diagnosis of troublesome GORD is secure, symptoms
fail to respond to PPI therapy, the patient is well informed about
the therapeutic choices, and there is evidence of major complica-
tions of GORD or the risk of complications (eg, aspiration)
(GRADE: no specific recommendation).39
No specific recommendation has been made by the committee
for managing GORD in CHILDREN, but CICADA recommends
against fundoplication for treating isolated cough in children
(Box 6).
Non-specific and refractory cough
Non-specific cough is a chronic cough that is not associated with
any of the cough pointers or cough-associated diagnoses. Investi-
gations with chest x-ray and spirometry are normal. Refractory
cough is a cough that persists after therapy. Most patients with
non-specific cough undergo spontaneous resolution or improve-
ment.
In ADULTS, the management of non-specific cough and refrac-
tory cough includes addressing patient stress and concerns
(GRADE: strong) and addressing exacerbating factors (GRADE:
weak). Consider an empirical trial of therapy involving an inhaled
corticosteroid (GRADE: strong), a PPI (GRADE: strong) and
speech pathology (GRADE: strong).
In CHILDREN, adopt the approach of counsel, watch, wait and
review40 (GRADE: strong). Address parental stress and concerns
(GRADE: strong). At each review in children and adults, look out
for specific pointers. CICADA recommends against the use of
narcotic cough suppressants in children (GRADE: strong).
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